ネフローゼ症候群市場 - 市場の洞察、疫学、市場予測：2034年

ネフローゼ症候群の市場規模は2022年に主要7ヶ国合計で約4億100万米ドルに達しました。予測期間中は大幅な成長が見込まれます。主要7ヶ国のうち、米国が2022年の市場を独占し、約50%で最大のシェアを占めています。2022年には、EU4ヶ国と英国が1億3,700万米ドルを獲得し、CAGRで大幅に増加すると予測されています。欧州諸国の中では、ドイツが2022年に最大の市場シェアを占め、英国、フランス、イタリアがこれに続きます。スペインは同年の市場シェアが最も低くなっています。2022年には日本だけでネフローゼ症候群市場全体の約16％を占め、調査期間中に大幅なCAGRで増加すると予測されます。ネフローゼ症候群治療市場全体の市場規模は、新しく効果的な治療法の出現により、予測期間中に成長が見込まれます。

ネフローゼ症候群は、低アルブミン血症の原因となる大量の蛋白尿によって定義される臨床症候群であり、その結果、高脂血症、浮腫、および様々な合併症を引き起こします。ネフローゼ症候群が長期化すると、感染症、栄養不良、心血管疾患のリスク上昇などの合併症を引き起こす可能性があります。したがって、正確な原因を突き止めることは、効果的な治療と包括的な管理のために不可欠です。

ネフローゼ症候群の診断プロセスには、臨床的評価、血清アルブミンおよび脂質濃度を評価するための血液検査、蛋白尿を検出するための尿検査、超音波検査などの画像診断が含まれます。さらに、根本的な原因を突き止めるために腎生検を行うこともあり、十分な情報に基づいた治療法の選択に役立ちます。このような包括的なアプローチにより、病態のニュアンスを十分に理解し、的確な診断と適切な介入を行うことができます。

ネフローゼ症候群の治療には、根本的な原因に対処し、血圧上昇、コレステロール値上昇、浮腫、感染感受性を緩和するための対策を実施することが含まれます。治療的介入は通常、薬物療法と食事療法からなります。ある種の降圧薬、特にACE阻害薬とARBはネフローゼ症候群に伴う腎臓病の進行を抑制する可能性があります。

当レポートでは、主要7ヶ国におけるネフローゼ症候群市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 ネフローゼ症候群市場概要

• 市場シェア（%）2020年の治療法別ネフローゼ症候群の分布
• 市場シェア（%）2034年の治療法別ネフローゼ症候群の分布

第4章 ネフローゼ症候群の疫学と市場調査手法

第5章 ネフローゼ症候群のエグゼクティブサマリー

第6章 主要な出来事

第7章 ネフローゼ症候群：疾患の背景と概要

• イントロダクション
• 病因
• 臨床症状
• 合併症
• 病態生理学
• 診断
• 管理と治療
• ガイドライン

第8章 疫学と患者数

• 主な調査結果
• 仮定と根拠：主要7ヶ国
• 主要7ヶ国で診断されたネフローゼ症候群の罹患症例の総数
• 米国
• EU4ヶ国と英国
• 日本

第9章 患者動向

第10章 上市済み薬剤

第11章 新興治療法

第12章 ネフローゼ症候群：主要7ヶ国市場分析

• 主な調査結果：市場
• 主要な市場予測の前提条件
• コンジョイント分析
• 市場の見通し
• 主要7ヶ国におけるネフローゼ症候群の市場規模
• 主要7ヶ国におけるネフローゼ症候群の市場規模、治療法別
• 米国におけるネフローゼ症候群の市場規模
• EU4ヶ国および英国におけるネフローゼ症候群の市場規模
• 日本におけるネフローゼ症候群の市場規模

第13章 KOLのビュー

第14章 SWOT分析

第15章 アンメットニーズ

第16章 市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

List of Tables

• Table 1: Summary of Nephrotic Syndrome Market and Epidemiology (2023-2034)
• Table 2: Key Events
• Table 3: Diagnostic Criteria for Nephrotic Syndrome
• Table 4: Potential Immunosuppressive Agents for Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
• Table 5: AAP Recommendations for Childhood Onset Nephrotic Syndrome
• Table 6: Nephrotic Syndrome in Children
• Table 7: Rituximab for the Treatment of Relapsing Steroid Sensitive Nephrotic Syndrome (1/2)
• Table 8: Rituximab for the Treatment of Relapsing Steroid Sensitive Nephrotic Syndrome (2/2)
• Table 9: Japanese guideline for nephrotic syndrome evidence-based clinical practice (1/4)
• Table 10: Japanese guideline for nephrotic syndrome evidence-based clinical practice (2/4)
• Table 11: Japanese guideline for nephrotic syndrome evidence-based clinical practice (3/4)
• Table 12: Japanese guideline for nephrotic syndrome evidence-based clinical practice (4/4)
• Table 13: KDIGO Recommendations for Treating Nephrotic Syndrome (1/2)
• Table 14: KDIGO Recommendations for Treating Nephrotic Syndrome (2/2)
• Table 15: Total Prevalent Cases of Nephrotic Syndrome in the 7MM (2020-2034)
• Table 16: Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the US (2020-2034)
• Table 17: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in the US (2020-2034)
• Table 18: Total Diagnosed Prevalent Cases of Nephrotic Syndrome in EU4 and the UK (2020-2034)
• Table 19: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in Germany (2020-2034)
• Table 20: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in France (2020-2034)
• Table 21: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in Italy (2020-2034)
• Table 22: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in Spain (2020-2034)
• Table 23: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in the UK (2020-2034)
• Table 24: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in EU4 and the UK (2020-2034)
• Table 25: Total Diagnosed Prevalent Cases of Nephrotic Syndrome in Japan (2020-2034)
• Table 26: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in Japan (2020-2034)
• Table 27: Key Cross of Marketed Drugs
• Table 28: LUPKYNIS (voclosporin), Clinical Trial Description, 2024
• Table 29: BENLYSTA (belimumab), Clinical Trial Description, 2024
• Table 30: INVOKANA (Canagliflozin), Clinical Trial Description, 2024
• Table 31: Sparsentan, Clinical Trial Description, 2024
• Table 32: TARPEYO (budesonide), Clinical Trial Description, 2024
• Table 33: Comparison of Emerging Drugs for Treatment
• Table 34: Inaxaplin (VX-147), Clinical Trial Description, 2024
• Table 35: Atrasentan, Clinical Trial Description, 2024
• Table 36: BI 764198, Clinical Trial Description, 2024
• Table 37: Obinutuzumab (RG7159, GA101), Clinical Trial Description, 2024
• Table 38: SNP-ACTH (1-39) Gel, Clinical Trial Description, 2024
• Table 39: VIS649 (sibeprenlimab), Clinical Trial Description, 2024
• Table 40: ASO Factor B (IONIS-FB-LRx, RG6299), Clinical Trial Description, 2024
• Table 41: Ianalumab (VAY736), Clinical Trial Description, 2024
• Table 42: Zetomipzomib (KZR-616), Clinical Trial Description, 2024
• Table 43: Povetacicept (ALPN-303), Clinical Trial Description, 2024
• Table 44: DMX-200, Clinical Trial Description, 2024
• Table 45: EMPAVELI (pegcetacoplan), Clinical Trial Description, 2024
• Table 46: LNP023 (iptacopan), Clinical Trial Description, 2024
• Table 47: Zigakibart (BION-1301), Clinical Trial Description, 2024
• Table 48: Atacicept, Clinical Trial Description, 2024
• Table 49: Saphnelo (anifrolumab), Clinical Trial Description, 2024
• Table 50: Felzartamab (MOR202), Clinical Trial Description, 2024
• Table 51: Key Market Forecast Assumptions for Obinutuzumab (GA101)
• Table 52: Key Market Forecast Assumptions for VIS649 (sibeprenlimab)
• Table 53: Key Market Forecast Assumptions for Zigakibart (BION-1301)
• Table 54: Key Market Forecast Assumptions for Atrasentan
• Table 55: Key Market Forecast Assumptions for Atacicept
• Table 56: Key Market Forecast Assumptions for ASO factor B (IONIS-FB-LRx, RG6299)
• Table 57: Key Market Forecast Assumptions for Saphnelo (anifrolumab)
• Table 58: Key Market Forecast Assumptions for EMPAVELI (pegcetacoplan)
• Table 59: Key Market Forecast Assumptions for LNP023 (iptacopan)
• Table 60: Key Market Forecast Assumptions for DMX-200
• Table 61: Key Market Forecast Assumptions for VX-147 (Inaxaplin)
• Table 62: Key Market Forecast Assumptions for Zetomipzomib (KZR-616)
• Table 63: Key Market Forecast Assumptions for FILSPARI (sparsentan)
• Table 64: Market Size of Nephrotic Syndrome in the 7MM, in USD million (2020-2034)
• Table 65: Market Size of Nephrotic Syndrome by Therapies in the 7MM, in USD million (2020-2034)
• Table 66: Market Size of Nephrotic Syndrome in the United States, in USD million (2020-2034)
• Table 67: Market Size of Nephrotic Syndrome by Therapies in the United States, in USD million (2020-2034)
• Table 68: Market Size of Nephrotic Syndrome in EU4 and the UK, in USD million (2020-2034)
• Table 69: Market Size of Nephrotic Syndrome by Therapies in Germany, in USD million (2020-2034)
• Table 70: Market Size of Nephrotic Syndrome by Therapies in France, in USD million (2020-2034)
• Table 71: Market Size of Nephrotic Syndrome by Therapies in Italy, in USD million (2020-2034)
• Table 72: Market Size of Nephrotic Syndrome by Therapies in Spain, in USD million (2020-2034)
• Table 73: Market Size of Nephrotic Syndrome by Therapies in the UK, in USD million (2020-2034)
• Table 74: Market Size of Nephrotic Syndrome by Therapies in EU4 and the UK, in USD million (2020-2034)
• Table 75: Market Size of Nephrotic Syndrome in Japan, in USD million (2020-2034)
• Table 76: Market Size of Nephrotic Syndrome by Therapies in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Etiology of Nephrotic Syndrome
• Figure 2: Common Signs of Nephrotic Syndrome
• Figure 3: Progression of Nephrotic Syndrome
• Figure 4: Complications Associated With Nephrotic Syndrome
• Figure 5: Structure of a Nephron in the Kidney
• Figure 6: Difference Between a Normal and Nephrotic Syndrome Glomerulus Filter
• Figure 7: Proteinuria and Hematuria Caused due to Nephrotic Syndrome
• Figure 8: Diagnosis Algorithm for Adults With Nephrotic Syndrome
• Figure 9: Treatment Algorithm for Nephrotic Syndrome
• Figure 10: Diagnostic Algorithm for Nephrotic Syndrome in Adults as per the American Family Physician (2016)
• Figure 11: IPNA Treatment and Management Recommendations for Children
• Figure 12: Management of a Steroid-sensitive Nephrotic Syndrome With Frequent Relapses and Steroid Dependence
• Figure 13: Management of a Steroid-resistant Nephrotic Syndrome
• Figure 14: Treatment Algorithm for nephrotic syndrome in a Newly Nephrotic Child
• Figure 15: Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the 7MM (2020-2034)
• Figure 16: Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the US (2020-2034)
• Figure 17: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in the US (2020-2034)
• Figure 18: Total Diagnosed Prevalent Cases of Nephrotic Syndrome in EU4 and the UK (2020-2034)
• Figure 19: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in EU4 and the UK (2020-2034)
• Figure 20: Total Diagnosed Prevalent Cases of Nephrotic Syndrome in Japan (2020-2034)
• Figure 21: Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in Japan (2020-2034)
• Figure 22: Nephrotic Syndrome Patient Journey
• Figure 23: Market Size of Nephrotic Syndrome in the 7MM, in USD million (2020-2034)
• Figure 24: Market Size of Nephrotic Syndrome by Therapies in the 7MM, in USD million (2020-2034)
• Figure 25: Market Size of Nephrotic Syndrome in the United States, in USD million (2020-2034)
• Figure 26: Market Size of Nephrotic Syndrome by Therapies in the United States, in USD million (2020-2034)
• Figure 27: Total Market Size of Nephrotic Syndrome in EU4 and the UK, in USD million (2020-2034)
• Figure 28: Market Size of Nephrotic Syndrome by Therapies in EU4 and the UK, in USD million (2020-2034)
• Figure 29: Market Size of Nephrotic Syndrome in Japan, in USD million (2020-2034)
• Figure 30: Market Size of Nephrotic Syndrome by Therapies in Japan, in USD million (2020-2034)
• Figure 31: Unmet Needs
• Figure 32: Health Technology Assessment
• Figure 33: Reimbursement Process in Germany
• Figure 34: Reimbursement Process in France
• Figure 35: Reimbursement Process in Italy
• Figure 36: Reimbursement Process in Spain
• Figure 37: Reimbursement Process in the United Kingdom
• Figure 38: Reimbursement Process in Japan

Key Highlights:

• The Nephrotic Syndrome market is projected to witness consistent growth throughout the forecast period (2023-2034). The market size of Nephrotic Syndrome in the 7MM is expected to increase, driven by the launch of emerging therapies.
• DelveInsight's analyst projects that among the total diagnosed prevalent cases of Nephrotic Syndrome in 7MM approximately 34% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 367 thousand diagnosed prevalent cases of Nephrotic Syndrome.
• In the 7MM, the market mainly consisted of corticosteroids, calcineurin inhibitors, ACE Inhibitors/ARB, immunosuppressant's, and others which generated nearly USD 401 million in 2022.
• The total market size of the Nephrotic Syndrome treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Atacicept, Atrasentan, Gazyva/Gazyvaro (obinutuzumab), Zigakibart (BION-1301), and others.

DelveInsight's "Nephrotic Syndrome - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Nephrotic Syndrome market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Nephrotic Syndrome market size from 2020 to 2034. The report also covers current Nephrotic Syndrome treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Disease Understanding and Treatment Algorithm

Nephrotic Syndrome Overview

Nephrotic syndrome is a clinical syndrome defined by massive proteinuria responsible for hypoalbuminemia, with resulting hyperlipidemia, edema, and various complications. Nephrotic syndrome may stem from diverse underlying factors, encompassing conditions like minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, lupus nephritis, diabetic nephropathy, infections, genetic disorders, specific medications, and more. Prolonged nephrotic syndrome can result in complications such as infections, malnutrition, and an elevated risk of cardiovascular disease. Consequently, accurately pinpointing the precise cause is imperative for effective treatment and comprehensive management.

From a pathological standpoint, nephrotic syndrome entails changes in the structure and function of the glomeruli, which are the small filtration units in the kidneys tasked with eliminating waste and surplus fluids from the blood. The key characteristics of nephrotic syndrome involve heightened permeability of the glomerular filtration barrier, leading to the excretion of proteins, notably albumin, in the urine.

Nephrotic Syndrome Diagnosis

The diagnostic process for nephrotic syndrome encompasses a clinical assessment, blood examinations to evaluate serum albumin and lipid concentrations, urine analyses to detect proteinuria and imaging modalities such as ultrasound. Additionally, a kidney biopsy may be undertaken to pinpoint the root cause, aiding in informed treatment choices. This comprehensive approach ensures a thorough understanding of the condition's nuances, facilitating precise diagnosis and tailored interventions.

Nephrotic Syndrome Treatment

The treatment of nephrotic syndrome involves addressing the fundamental cause and implementing measures to mitigate elevated blood pressure, elevated cholesterol levels, edema, and infection susceptibility. Therapeutic interventions typically comprise medications and dietary modifications. Certain antihypertensive drugs, specifically ACE inhibitors and ARBs, exhibit the potential to decelerate kidney diseases associated with nephrotic syndrome.

Nephrotic Syndrome Epidemiology

As the market is derived using the patient-based model, the Nephrotic Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Nephrotic Syndrome and Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

As per DelveInsight's estimations, the total diagnosed prevalent cases of Nephrotic Syndrome in the 7MM were approximately 786 thousand in 2022 and are projected to increase during the forecast period.

• The overall count of individuals diagnosed with Nephrotic Syndrome in the United States was approximately 268 thousand in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
• Among the 7MM, the US accounted for nearly 214 thousand cases of Primary Glomerulonephropathies, and 54 thousand cases of Secondary Glomerulonephropathies. These cases are expected to increase during the forecast period (2023-2034).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of Nephrotic Syndrome, with about 98 thousand cases, followed by the UK and France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• In Japan, there were around 151 thousand diagnosed prevalent cases of Nephrotic Syndrome in 2022. These cases are expected to decrease by 2034.

Nephrotic Syndrome Drug Chapters

The drug chapter segment of the Nephrotic Syndrome report encloses a detailed analysis of Nephrotic Syndrome marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Nephrotic Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

Atacicept: Vera Therapeutics

Atacicept developed by Vera Therapeutics, is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgA nephropathy and lupus nephritis.

Atrasentan: Chinook Therapeutics/ Novartis

Atrasentan is an oral potent and selective endothelin A (ETA) receptor antagonist, which works by inhibiting the ETA receptor activation of multiple renal cell types. This blockade reduces kidney inflammation and fibrosis, thus leading to reduced proteinuria in patients with chronic kidney disease.

Note: Detailed emerging therapies assessment will be provided in the final report of Nephrotic Syndrome.

Nephrotic Syndrome Market Outlook

Nephrotic syndrome is a collection of symptoms that signal impaired kidney function. These symptoms encompass proteinuria, hypoalbuminemia, edema, hyperlipidemia, and various other associated complications.

The management of nephrotic syndrome entails addressing underlying medical conditions contributing to its onset. Healthcare professionals may prescribe medications and dietary modifications to regulate symptoms and address complications associated with nephrotic syndrome. Currently, there are no authorized therapies specifically designed for treating nephrotic syndrome, and the predominant treatment strategies often involve off-label approaches. Corticosteroids like prednisone, cyclophosphamide, and cyclosporine are employed to induce remission in nephrotic syndrome. Diuretics are utilized to alleviate edema, while angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are employed to diminish proteinuria.

Progress in the treatment of nephrotic syndrome has transformed patient care, integrating lifestyle modifications, medications, and procedures. Emerging therapies, including monoclonal antibodies and antagonists targeting APRIL and BAFF, among others, hold the potential for improving patient outcomes. Continuous research and ongoing clinical trials are shaping a promising future for nephrotic syndrome treatment, providing optimism for a world with decreased morbidity and mortality.

The market for Nephrotic Syndrome is expected to experience positive growth with the approval of potential drugs like Atacicept, Atrasentan, Gazyva/Gazyvaro (obinutuzumab), Zigakibart (BION-1301), and others.

• The Nephrotic Syndrome market's total size in the 7MM reached approximately USD 401 million in 2022. Projections indicate a substantial growth during the forecast period.
• Out of the 7MM, the United States dominated the market in 2022, representing the largest share at nearly 50%.
• In 2022, EU4 and the UK captured an estimated USD 137 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest market share in 2022, followed by the UK, France, and Italy. Spain accounted for the least market in the same year.
• Japan alone represented approximately 16% of the total Nephrotic Syndrome market in 2022, projected to increase at a substantial CAGR during the study period.
• The total market size of the Nephrotic Syndrome treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.

Nephrotic Syndrome Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, Atacicept in the US is expected to be launched by 2027.

Further detailed analysis of emerging therapies drug uptake in the report…

Nephrotic Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Nephrotic Syndrome emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Nephrotic Syndrome evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Boston Children's Hospital, Ohio State University, Montefiore Medical Center, Hannover Medical School, Hannover, Hopital Robert-Debre, APHP, Paris, Istituto G. Gaslini, Genoa, Hospital Universitario Fundacion Jimenez Diaz, UCL Department of Renal Medicine, National Health Service, England, Fukushima Medical University, Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Japan, and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Nephrotic Syndrome market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of Nephrotic Syndrome, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Nephrotic Syndrome market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Nephrotic Syndrome market.

Nephrotic Syndrome Report Insights

• Patient Population
• Therapeutic Approaches
• Nephrotic Syndrome Pipeline Analysis
• Nephrotic Syndrome Market Size and Trends
• Existing and Future Market Opportunity

Nephrotic Syndrome Report Key Strengths

• 12 years Forecast
• The 7MM Coverage
• Nephrotic Syndrome Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Nephrotic Syndrome Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

• What was the Nephrotic Syndrome total market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?
• What unmet needs are associated with the current treatment market of Nephrotic Syndrome?
• What are the patents of emerging therapies for Nephrotic Syndrome?
• Which drug is going to be the largest contributor by 2034?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Nephrotic Syndrome? What will be the growth opportunities across the 7MM concerning the patient population of Nephrotic Syndrome?
• What is the historical and forecasted Nephrotic Syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for Nephrotic Syndrome and why?
• What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating Nephrotic Syndrome? What are the current guidelines for treating Nephrotic Syndrome in the US and Europe?
• How many companies are developing therapies for treating Nephrotic Syndrome?
• How many emerging therapies are in the mid-stage and late stage of development for treating Nephrotic Syndrome?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Nephrotic Syndrome?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted markets of Nephrotic Syndrome?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Nephrotic Syndrome Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1. What is the forecast period covered in the report?

• The Nephrotic Syndrome Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Nephrotic Syndrome market?

• The Nephrotic Syndrome emerging market many drugs. The major key players developing therapies for Nephrotic Syndrome are Vera Therapeutics, Novartis, Chinook Therapeutics, AstraZeneca, Hoffmann-La Roche, Otsuka Pharmaceutical Development and Commercialization, Visterra and others.

3. How is the market size estimated in the forecast report?

• The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as prevalent cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Nephrotic Syndrome market?

• The increase in diagnosed prevalent cases of Nephrotic Syndrome and the launch of emerging therapies are attributed to be the key drivers for increasing Nephrotic Syndrome market.

5. What is the expected impact of emerging therapies or advancements in Nephrotic Syndrome treatment on the market?

• Introducing new therapies, advancements in disease understanding and diagnostic techniques, and innovations in treatment approaches can significantly impact the Nephrotic Syndrome treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

• The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Nephrotic Syndrome market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Nephrotic Syndrome Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Nephrotic Syndrome by Therapies in 2020
• 3.2. Market Share (%) Distribution of Nephrotic Syndrome by Therapies in 2034

4. Epidemiology and Market Methodology of Nephrotic Syndrome

5. Executive Summary of Nephrotic Syndrome

6. Key Events

7. Nephrotic Syndrome: Disease Background and Overview

• 7.1. Introduction
• 7.2. Etiology
• 7.3. Clinical Manifestation
• 7.4. Complications
• 7.5. Pathophysiology
• 7.6. Diagnosis
  • 7.6.1. Differential Diagnosis
  • 7.6.2. Diagnostic Algorithm
• 7.7. Management and Treatment
  • 7.7.1. Treatment Algorithm
• 7.8. Guidelines
  • 7.8.1. Diagnosis and Management of Nephrotic Syndrome in Adults: American Family Physician (2016)
  • 7.8.2. International Pediatric Nephrology Association (IPNA) Clinical Practice Recommendations for the Diagnosis and Management of Children with Steroid-resistant Nephrotic Syndrome (2022)
  • 7.8.3. Clinical Practice Guidelines for Nephrotic Syndrome (2022)
  • 7.8.4. Management of Childhood Onset Nephrotic Syndrome: The American Academy of Pediatrics (AAP)
  • 7.8.5. Clinical Commissioning Policy: National Health Service (NHS)
  • 7.8.6. Evidence-Based Clinical Practice Guidelines for Nephrotic Syndrome (2014)
  • 7.8.7. International Society of Nephrology: Kidney Disease Improving Global Outcomes (KDIGO), 2012
  • 7.8.8. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
  • 8.2.1. FSGS
  • 8.2.2. IgA Nephropathy
  • 8.2.3. Membranous Nephropathy
  • 8.2.4. Others
• 8.3. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the 7MM
• 8.4. The United States
  • 8.4.1. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in the United States
  • 8.4.2. Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in EU4 and the UK
  • 8.5.2. Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of Nephrotic Syndrome in Japan
  • 8.6.2. Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in Japan

9. Patient Journey

10. Marketed Drugs

• 10.1. Key Competitors
• 10.2. LUPKYNIS (voclosporin): Aurinia Pharmaceuticals/Otsuka Pharmaceutical
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Clinical Development
  • 10.2.5. Clinical Trials Information
  • 10.2.6. Safety and Efficacy
  • 10.2.7. Product Profile
• 10.3. BENLYSTA (belimumab): GSK
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Clinical Development
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy
  • 10.3.6. Product Profile
• 10.4. INVOKANA (Canagliflozin): Johnson & Johnson
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Developmental Activities
  • 10.4.4. Clinical Development
  • 10.4.5. Clinical Trials Information
  • 10.4.6. Safety and Efficacy
  • 10.4.7. Product Profile
• 10.5. FILSPARI (Sparsentan): Travere Therapeutics/CSL Vifor
  • 10.5.1. Product Description
  • 10.5.2. Regulatory Milestones
  • 10.5.3. Other Developmental Activities
  • 10.5.4. Clinical Development
  • 10.5.5. Clinical Trials Information
  • 10.5.6. Safety and Efficacy
  • 10.5.7. Product Profile
• 10.6. TARPEYO (budesonide): Calliditas Therapeutics AB
  • 10.6.1. Product Description
  • 10.6.2. Regulatory Milestones
  • 10.6.3. Other Developmental Activities
  • 10.6.4. Clinical Development
  • 10.6.5. Clinical Trials Information
  • 10.6.6. Safety and Efficacy
  • 10.6.7. Product Profile

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Inaxaplin (VX-147): Vertex Pharmaceuticals
  • 11.2.1. Product Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Development
  • 11.2.4. Clinical Trials Information
  • 11.2.5. Safety and Efficacy
  • 11.2.6. Product Profile
  • 11.2.7. Analysts' Views
• 11.3. Atrasentan: Chinook Therapeutics/ Novartis
  • 11.3.1. Product Description
  • 11.3.2. Other Development Activities
  • 11.3.3. Clinical Development
  • 11.3.4. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Product Profile
  • 11.3.7. Analysts' Views
• 11.4. BI 764198: Boehringer Ingelheim
  • 11.4.1. Product Description
  • 11.4.2. Clinical Development
  • 11.4.3. Clinical Trials Information
  • 11.4.4. Product Profile
  • 11.4.5. Analysts' Views
• 11.5. Obinutuzumab (RG7159, GA101): Hoffmann-La Roche/Biogen
  • 11.5.1. Product Description
  • 11.5.2. Other Development Activities
  • 11.5.3. Clinical Development
  • 11.5.4. Clinical Trials Information
  • 11.5.5. Safety and Efficacy
  • 11.5.6. Product Profile
  • 11.5.7. Analysts' Views
• 11.6. SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals
  • 11.6.1. Product Description
  • 11.6.2. Other Development Activities
  • 11.6.3. Clinical Development
  • 11.6.4. Clinical Trials Information
  • 11.6.5. Safety and Efficacy
  • 11.6.6. Product Profile
  • 11.6.7. Analysts' Views
• 11.7. VIS649 (sibeprenlimab): Otsuka Pharmaceutical Development & Commercialization/Visterra
  • 11.7.1. Product Description
  • 11.7.2. Other Development Activities
  • 11.7.3. Clinical Development
  • 11.7.4. Clinical Trials Information
  • 11.7.5. Safety and Efficacy
  • 11.7.6. Product Profile
  • 11.7.7. Analysts' Views
• 11.8. ASO factor B (IONIS-FB-LRx, RG6299): Hoffmann-La Roche/Ionis Pharmaceuticals
  • 11.8.1. Product Description
  • 11.8.2. Other Development Activities
  • 11.8.3. Clinical Development
  • 11.8.4. Clinical Trials Information
  • 11.8.5. Safety and Efficacy
  • 11.8.6. Product Profile
  • 11.8.7. Analysts' Views
• 11.9. Ianalumab (VAY736): Novartis
  • 11.9.1. Product Description
  • 11.9.2. Clinical Development
  • 11.9.3. Clinical Trials Information
  • 11.9.4. Safety and Efficacy
  • 11.9.5. Product Profile
  • 11.9.6. Analysts' Views
• 11.1. Zetomipzomib (KZR-616): Kezar Life Sciences
  • 11.10.1. Product Description
  • 11.10.2. Other Development Activities
  • 11.10.3. Clinical Development
  • 11.10.4. Clinical Trials Information
  • 11.10.5. Safety and Efficacy
  • 11.10.6. Product Profile
  • 11.10.7. Analysts' Views
• 11.11. Povetacicept (ALPN-303): Alpine Immune Sciences
  • 11.11.1. Product Description
  • 11.11.2. Other Development Activities
  • 11.11.3. Clinical Development
  • 11.11.4. Clinical Trials Information
  • 11.11.5. Safety and Efficacy
  • 11.11.6. Product Profile
  • 11.11.7. Analysts' Views
• 11.12. DMX-200: Dimerix Bioscience/Advanz Pharma
  • 11.12.1. Product Description
  • 11.12.2. Other Development Activities
  • 11.12.3. Clinical Development
  • 11.12.4. Clinical Trials Information
  • 11.12.5. Safety and Efficacy
  • 11.12.6. Product Profile
  • 11.12.7. Analyst Views
• 11.13. EMPAVELI (pegcetacoplan): Apellis Pharmaceuticals
  • 11.13.1. Product Description
  • 11.13.2. Other Developmental Activities
  • 11.13.3. Clinical Development
  • 11.13.4. Clinical Trials Information
  • 11.13.5. Safety and Efficacy
  • 11.13.6. Product Profile
  • 11.13.7. Analyst Views
• 11.14. LNP023 (iptacopan): Novartis Pharmaceuticals
  • 11.14.1. Product Description
  • 11.14.2. Other Developmental Activities
  • 11.14.3. Clinical Development
  • 11.14.4. Clinical Trials Information
  • 11.14.5. Safety and Efficacy
  • 11.14.6. Product Profile
  • 11.14.7. Analyst Views
• 11.15. Zigakibart (BION-1301): Chinook Therapeutics, Inc./Novartis
  • 11.15.1. Product Description
  • 11.15.2. Other Developmental Activities
  • 11.15.3. Clinical Development
  • 11.15.4. Clinical Trials Information
  • 11.15.5. Safety and Efficacy
  • 11.15.6. Product Profile
  • 11.15.7. Analyst Views
• 11.16. Atacicept: Vera Therapeutics, Inc.
  • 11.16.1. Product Description
  • 11.16.2. Other Developmental Activities
  • 11.16.3. Clinical Development
  • 11.16.4. Clinical Trials Information
  • 11.16.5. Safety and Efficacy
  • 11.16.6. Product Profile
  • 11.16.7. Analyst Views
• 11.17. Saphnelo (anifrolumab): AstraZeneca
  • 11.17.1. Product Description
  • 11.17.2. Clinical Development
  • 11.17.3. Clinical Trials Information
  • 11.17.4. Safety and Efficacy
  • 11.17.5. Product Profile
  • 11.17.6. Analyst Views
• 11.18. Felzartamab (MOR202): HI-Bio
  • 11.18.1. Product Description
  • 11.18.2. Other Developmental Activities
  • 11.18.3. Clinical Development
  • 11.18.4. Clinical Trials Information
  • 11.18.5. Safety and Efficacy
  • 11.18.6. Product Profile
  • 11.18.7. Analyst Views

12. Nephrotic Syndrome: Seven Major Market Analysis

• 12.1. Key Findings: Market
• 12.2. Key Market Forecast Assumptions
• 12.3. Conjoint Analysis
• 12.4. Market Outlook
• 12.5. Market Size of Nephrotic Syndrome in the 7MM
• 12.6. Market size of Nephrotic Syndrome by Therapies in the 7MM
• 12.7. Market Size of Nephrotic Syndrome in the United States
  • 12.7.1. Total Market Size of Nephrotic Syndrome
  • 12.7.2. Market Size of Nephrotic Syndrome by Therapies
• 12.8. Market Size of Nephrotic Syndrome in EU4 and the UK
  • 12.8.1. Total Market Size of Nephrotic Syndrome in EU4 and the UK
  • 12.8.2. Market Size of Nephrotic Syndrome by Therapies
• 12.9. Market Size of Nephrotic Syndrome in Japan
  • 12.9.1. Total Market Size of Nephrotic Syndrome in Japan
  • 12.9.2. Market Size of Nephrotic Syndrome by Therapies

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Center for Medicare & Medicaid Services (CMS)
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer